About Deep Pharma Intelligence

Deep Pharma Intelligence (DPI) is a leading UK-based strategic and investment intelligence agency focused on the emerging markets in the Pharmaceutical, Biotech, MedTech and Healthcare Tech industries.

Deep Pharma Intelligence is a joint venture created by **Deep Knowledge Analytics Pharma Division** and **BPT Analytics (BiopharmaTrend)** – two highly specialized think tanks in the area of biotech innovation profiling, business intelligence, and biotech investment advisory. DPI is dedicated to producing powerful data mining and visualization systems, interactive analytics tools, and industry reports offering deep technical insights, business intelligence, and strategic guidance in the high growth and significant opportunity areas of the pharmaceutical industry, including artificial intelligence (AI) in drug discovery, emerging therapeutic targets and drug modalities, new therapies and technologies, promising startups, and more.

Our Value Proposition:

Open Access and Proprietary Reports

Deep Pharma Intelligence is producing regular open access reports covering emerging bio-pharmaceutical markets -- technologies, innovations, companies, and trends.Our clients and partners can enjoy access to proprietary reports, featuring additional in-depth research conducted by our team on regular basis. IT-Platform and Big Data

Analytics Dashboard

Our company is building a sophisticated cloud-based engine for advanced market and business intelligence in the pharmaceutical and healthcare industries. It includes data mining engine, infrastructure for expert data curation, and advanced visualization dashboards.
Visit our prototype dashboard to learn more:
www.deep-pharma.tech/dashboard

Strategic Consulting and Investment Advisory

Deep Pharma Intelligence offers a comprehensive range of consulting services, including comprehensive support for growing business in the bio-pharmaceutical industry and related areas. It includes a wide range of services from market and competitor research, technology scouting and due diligence, to investment landscape profiling and comprehensive analytics support for life science organizations and financial institutions.

"A Landscape of Cell Therapy Technologies in Healthcare Q2 2021" (Stem Cells and CAR-Ts)

The 115-page report is the first systematic study of the cell therapy industry by Deep Pharma Intelligence, that serves as a landscape overview and a beginning of a new series of reports and analytical studies of cell therapy industry. This report specifically focuses on Stem Cell technologies and CAR-T therapies and covers more than **400 companies** and **400 investors** worldwide.

Analysis of Top 50 Cell Therapy Companies: R&D Maturity vs Application Focus



Notable Investment Deals in 2020-2021 (in million US$)



DEEP PHARMA INTELLIGENCE

Deep Pharma Intelligence

Cell Therapies in Healthcare Landscape Overview Q2 2021 (Stem Cells and CAR-Ts)

Cell Therapies in Healthcare Landscape Overview Q2 2021 (Stem Cells and CAR-T)

Companies - 390
Investors - 200
Corporations - 15



DEEP PHARMA INTELLIGENCE

Comparison of Top 50 Cell Therapy Companies: R&D Maturity vs Funding Level